Cargando…

TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic (18)F-FET PET?

OBJECTIVE: The mutation of the ‘telomerase reverse transcriptase gene promoter’ (TERTp) has been identified as an important factor for individual prognostication and tumorigenesis and will be implemented in upcoming glioma classifications. Uptake characteristics on dynamic (18)F-FET PET have been sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unterrainer, Marcus, Ruf, Viktoria, von Rohr, Katharina, Suchorska, Bogdana, Mittlmeier, Lena Maria, Beyer, Leonie, Brendel, Matthias, Wenter, Vera, Kunz, Wolfgang G., Bartenstein, Peter, Herms, Jochen, Niyazi, Maximilian, Tonn, Jörg C., Albert, Nathalie Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121001/ https://www.ncbi.nlm.nih.gov/pubmed/33996563 http://dx.doi.org/10.3389/fonc.2021.645316

Ejemplares similares

(18)F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Combination of pre-treatment dynamic [(18)F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma
por: Li, Zhicong, et al.
Publicado: (2022)

Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [(18)F]FET PET radiomics
por: Li, Zhicong, et al.
Publicado: (2021)

L-type amino acid transporter (LAT) 1 expression in (18)F-FET-negative gliomas
por: Vettermann, Franziska J., et al.
Publicado: (2021)

Can Radiomics Provide Additional Information in [(18)F]FET-Negative Gliomas?
por: von Rohr, Katharina, et al.
Publicado: (2022)

PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging
por: Holzgreve, Adrien, et al.
Publicado: (2021)

Towards standardization of (18)F-FET PET imaging: do we need a consistent method of background activity assessment?
por: Unterrainer, Marcus, et al.
Publicado: (2017)

Voxel-wise analysis of dynamic (18)F-FET PET: a novel approach for non-invasive glioma characterisation
por: Vomacka, Lena, et al.
Publicado: (2018)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

(18)F-FET PET radiomics-based survival prediction in glioblastoma patients receiving radio(chemo)therapy
por: Wiltgen, Tun, et al.
Publicado: (2022)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties?
por: Romagna, Alexander, et al.
Publicado: (2016)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas
por: Kaiser, Lena, et al.
Publicado: (2021)

Monitoring of Tumor Growth with [(18)F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches
por: Holzgreve, Adrien, et al.
Publicado: (2016)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

(68)Ga-EMP-100 PET/CT—a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer
por: Unterrainer, Lena M., et al.
Publicado: (2022)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

TSPO PET signal using [(18)F]GE180 is associated with survival in recurrent gliomas
por: Quach, Stefanie, et al.
Publicado: (2022)

FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
por: Carles, Montserrat, et al.
Publicado: (2021)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

Longitudinal [(18)F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model
por: Holzgreve, Adrien, et al.
Publicado: (2022)

Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours
por: Beyer, Leonie, et al.
Publicado: (2021)

Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
por: Delker, Astrid, et al.
Publicado: (2023)

Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status
por: Weller, Jonathan, et al.
Publicado: (2023)

Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Detection of Splenic Tissue Using (99m)Tc-Labelled Denatured Red Blood Cells Scintigraphy—A Quantitative Single Center Analysis
por: Holzgreve, Adrien, et al.
Publicado: (2022)

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022)

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?
por: Quach, Stefanie, et al.
Publicado: (2022)

(68)Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Investigation of image-based lesion and kidney dosimetry protocols for (177)Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
por: Resch, Sandra, et al.
Publicado: (2023)

Data on specificity of [(18)F]GE180 uptake for TSPO expression in rodent brain and myocardium
por: Deussing, Maximilian, et al.
Publicado: (2018)

(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
por: Ahmaddy, Freba, et al.
Publicado: (2021)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Deciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution
por: Bartos, Laura M., et al.
Publicado: (2023)

Molecular Imaging with (18)F-FDG PET/CT and (99m)Tc-MIBI SPECT/CT in Osteitis Fibrosa Cystica Generalisata
por: Holzgreve, Adrien, et al.
Publicado: (2021)

PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
por: Unterrainer, Marcus, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v13jo5e2jsmnfrqevjs08be9mv